paclitaxel  (Millipore)


Bioz Verified Symbol Millipore is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99
    Name:
    Paclitaxel
    Description:
    Chemical structure taxoide
    Catalog Number:
    t7191
    Price:
    None
    Applications:
    Paclitaxel has been used to study its effects on tumor regression in mouse models of pancreatic ductal adenocarcinoma. Paclitaxel has also been used as an internal standard for chromatographic assays of docetaxel. Furthermore, paclitaxel has been used to analyze its effects on Caenorhabditis elegans embryos.
    Buy from Supplier


    Structured Review

    Millipore paclitaxel
    Paclitaxel
    Chemical structure taxoide
    https://www.bioz.com/result/paclitaxel/product/Millipore
    Average 99 stars, based on 755 article reviews
    Price from $9.99 to $1999.99
    paclitaxel - by Bioz Stars, 2020-09
    99/100 stars

    Images

    1) Product Images from "Paclitaxel reduces axonal Bclw to initiate IP3R1-dependent axon degeneration"

    Article Title: Paclitaxel reduces axonal Bclw to initiate IP3R1-dependent axon degeneration

    Journal: Neuron

    doi: 10.1016/j.neuron.2017.09.034

    The Bclw BH4 domain is sufficient to prevent paclitaxel-induced axon degeneration (A) Schematic of stabilized alpha-helix of Bcl2 domain (SAHB) peptides modeled after the BH4 domains of Bclw (PDB ID 4CIM, aa 12-31), Bcl2 (PDB ID 2XA0, aa 13-32), and Bclx L (PDB ID 4QVE, aa 6-26). (B) Percent release of ANTS/DPX encapsulated liposomes in the presence of Bax, Bim SAHB A2 , and/or Bclw BH4 SAHB A as indicated; n=3; data represent mean ± SD. (C) Axons from compartmented cultures after protein transfection with FITC-BH4 SAHB peptides of Bclw, Bcl2, or Bclx L showing FITC signal (left) and Tuj1 signal (right); scale bar = 20 µm. (D) Degeneration index of axons treated with paclitaxel or DMSO after protein transfection of FITC-BH4 SAHB-Bclw, Bcl2, or Bclx L into axons; *p
    Figure Legend Snippet: The Bclw BH4 domain is sufficient to prevent paclitaxel-induced axon degeneration (A) Schematic of stabilized alpha-helix of Bcl2 domain (SAHB) peptides modeled after the BH4 domains of Bclw (PDB ID 4CIM, aa 12-31), Bcl2 (PDB ID 2XA0, aa 13-32), and Bclx L (PDB ID 4QVE, aa 6-26). (B) Percent release of ANTS/DPX encapsulated liposomes in the presence of Bax, Bim SAHB A2 , and/or Bclw BH4 SAHB A as indicated; n=3; data represent mean ± SD. (C) Axons from compartmented cultures after protein transfection with FITC-BH4 SAHB peptides of Bclw, Bcl2, or Bclx L showing FITC signal (left) and Tuj1 signal (right); scale bar = 20 µm. (D) Degeneration index of axons treated with paclitaxel or DMSO after protein transfection of FITC-BH4 SAHB-Bclw, Bcl2, or Bclx L into axons; *p

    Techniques Used: Transfection

    Loss of Bclw exacerbates paclitaxel-induced neuropathy in vivo . (A) Thermal pain threshold measured as time to lick or withdraw hindpaw on a 50°C hot-plate. (B) Mechanical pain threshold determined from response to von Frey filaments. (C-F) Quantification and representative images of Tuj1 positive sensory fibers (green, arrowheads) entering the epidermis per 225 µm epidermal length in thick (C-D) and thin (E-F) skin, DAPI counterstain (blue); scale bar = 25 µm; *p
    Figure Legend Snippet: Loss of Bclw exacerbates paclitaxel-induced neuropathy in vivo . (A) Thermal pain threshold measured as time to lick or withdraw hindpaw on a 50°C hot-plate. (B) Mechanical pain threshold determined from response to von Frey filaments. (C-F) Quantification and representative images of Tuj1 positive sensory fibers (green, arrowheads) entering the epidermis per 225 µm epidermal length in thick (C-D) and thin (E-F) skin, DAPI counterstain (blue); scale bar = 25 µm; *p

    Techniques Used: In Vivo

    Paclitaxel reduces axonal Bclw mRNA and protein levels bclw (A), bcl2 (D) and bclx L (G) mRNA analyzed by qRT-PCR from cell body or axon lysate of compartmented cultures after 24 hours of paclitaxel or vehicle treatment to axons. Data normalized to gapdh ; *p
    Figure Legend Snippet: Paclitaxel reduces axonal Bclw mRNA and protein levels bclw (A), bcl2 (D) and bclx L (G) mRNA analyzed by qRT-PCR from cell body or axon lysate of compartmented cultures after 24 hours of paclitaxel or vehicle treatment to axons. Data normalized to gapdh ; *p

    Techniques Used: Quantitative RT-PCR

    Paclitaxel reduces translation of Bclw via reduction of SFPQ (A) Western blot and (B) quantification of SFPQ protein from cell body or distal axon lysate of compartmented cultures after 24 hours of paclitaxel treatment to axons; data normalized to actin; *p
    Figure Legend Snippet: Paclitaxel reduces translation of Bclw via reduction of SFPQ (A) Western blot and (B) quantification of SFPQ protein from cell body or distal axon lysate of compartmented cultures after 24 hours of paclitaxel treatment to axons; data normalized to actin; *p

    Techniques Used: Western Blot

    Axonal Bclw prevents paclitaxel-induced degeneration (A) Binarized images of Tuj1 immunostaining of axons treated with paclitaxel or vehicle after protein transfection with Bclw, Bcl2, Bclx L . (B) Degeneration index of (A) and untransfected (Untrans) control; *p
    Figure Legend Snippet: Axonal Bclw prevents paclitaxel-induced degeneration (A) Binarized images of Tuj1 immunostaining of axons treated with paclitaxel or vehicle after protein transfection with Bclw, Bcl2, Bclx L . (B) Degeneration index of (A) and untransfected (Untrans) control; *p

    Techniques Used: Immunostaining, Transfection

    Paclitaxel acts locally to induce axon degeneration without cell body apoptosis (A) Tuj1 immunostaining and corresponding binarized images of axons of E15 DRG neurons grown in compartmented cultures treated with 30 nM paclitaxel or DMSO vehicle control for 24 hours to cell body (left) or distal axon (right) compartments; scale bar = 40 µm. Red boxes outline regions shown at higher magnification in the center panels. Features characteristic of degenerating axons are seen: red arrowheads indicate a “beads on a string” appearance and the red lines indicate interruptions in Tuj1 continuity. (B) Quantification of axonal degeneration: ratio of area of fragmented axons to total axon area (degeneration index); *p
    Figure Legend Snippet: Paclitaxel acts locally to induce axon degeneration without cell body apoptosis (A) Tuj1 immunostaining and corresponding binarized images of axons of E15 DRG neurons grown in compartmented cultures treated with 30 nM paclitaxel or DMSO vehicle control for 24 hours to cell body (left) or distal axon (right) compartments; scale bar = 40 µm. Red boxes outline regions shown at higher magnification in the center panels. Features characteristic of degenerating axons are seen: red arrowheads indicate a “beads on a string” appearance and the red lines indicate interruptions in Tuj1 continuity. (B) Quantification of axonal degeneration: ratio of area of fragmented axons to total axon area (degeneration index); *p

    Techniques Used: Immunostaining

    2) Product Images from "The Fate of β-Hexabromocyclododecane in Female C57BL/6 Mice"

    Article Title: The Fate of β-Hexabromocyclododecane in Female C57BL/6 Mice

    Journal: Toxicological Sciences

    doi: 10.1093/toxsci/kft121

    Excretion of β-HBCD-derived radioactivity over time following single doses of 3, 30, or 100mg/kg by gavage. Values are the mean ± SD of four mice. *The value is significantly higher than that for the 100mg/kg group ( p
    Figure Legend Snippet: Excretion of β-HBCD-derived radioactivity over time following single doses of 3, 30, or 100mg/kg by gavage. Values are the mean ± SD of four mice. *The value is significantly higher than that for the 100mg/kg group ( p

    Techniques Used: Derivative Assay, Radioactivity, Mouse Assay

    β-HBCD-derived radioactivity remaining in tissues 4 days following single doses of 3, 30, or 100mg/kg by gavage. Values are the mean ± SD for three to four mice. *The value is significantly higher than that for the 3mg/kg group ( p
    Figure Legend Snippet: β-HBCD-derived radioactivity remaining in tissues 4 days following single doses of 3, 30, or 100mg/kg by gavage. Values are the mean ± SD for three to four mice. *The value is significantly higher than that for the 3mg/kg group ( p

    Techniques Used: Derivative Assay, Radioactivity, Mouse Assay

    β-HBCD-derived radioactivity remaining in tissues and cumulatively excreted 24h following oral and iv administration of 3mg/kg. Values are for the mean ± SD of four mice. *The value is significantly different from the corresponding value
    Figure Legend Snippet: β-HBCD-derived radioactivity remaining in tissues and cumulatively excreted 24h following oral and iv administration of 3mg/kg. Values are for the mean ± SD of four mice. *The value is significantly different from the corresponding value

    Techniques Used: Derivative Assay, Radioactivity, Mouse Assay

    3) Product Images from "Paclitaxel reduces axonal Bclw to initiate IP3R1-dependent axon degeneration"

    Article Title: Paclitaxel reduces axonal Bclw to initiate IP3R1-dependent axon degeneration

    Journal: Neuron

    doi: 10.1016/j.neuron.2017.09.034

    The Bclw BH4 domain is sufficient to prevent paclitaxel-induced axon degeneration (A) Schematic of stabilized alpha-helix of Bcl2 domain (SAHB) peptides modeled after the BH4 domains of Bclw (PDB ID 4CIM, aa 12-31), Bcl2 (PDB ID 2XA0, aa 13-32), and Bclx L (PDB ID 4QVE, aa 6-26). (B) Percent release of ANTS/DPX encapsulated liposomes in the presence of Bax, Bim SAHB A2 , and/or Bclw BH4 SAHB A as indicated; n=3; data represent mean ± SD. (C) Axons from compartmented cultures after protein transfection with FITC-BH4 SAHB peptides of Bclw, Bcl2, or Bclx L showing FITC signal (left) and Tuj1 signal (right); scale bar = 20 µm. (D) Degeneration index of axons treated with paclitaxel or DMSO after protein transfection of FITC-BH4 SAHB-Bclw, Bcl2, or Bclx L into axons; *p
    Figure Legend Snippet: The Bclw BH4 domain is sufficient to prevent paclitaxel-induced axon degeneration (A) Schematic of stabilized alpha-helix of Bcl2 domain (SAHB) peptides modeled after the BH4 domains of Bclw (PDB ID 4CIM, aa 12-31), Bcl2 (PDB ID 2XA0, aa 13-32), and Bclx L (PDB ID 4QVE, aa 6-26). (B) Percent release of ANTS/DPX encapsulated liposomes in the presence of Bax, Bim SAHB A2 , and/or Bclw BH4 SAHB A as indicated; n=3; data represent mean ± SD. (C) Axons from compartmented cultures after protein transfection with FITC-BH4 SAHB peptides of Bclw, Bcl2, or Bclx L showing FITC signal (left) and Tuj1 signal (right); scale bar = 20 µm. (D) Degeneration index of axons treated with paclitaxel or DMSO after protein transfection of FITC-BH4 SAHB-Bclw, Bcl2, or Bclx L into axons; *p

    Techniques Used: Transfection

    Loss of Bclw exacerbates paclitaxel-induced neuropathy in vivo . (A) Thermal pain threshold measured as time to lick or withdraw hindpaw on a 50°C hot-plate. (B) Mechanical pain threshold determined from response to von Frey filaments. (C-F) Quantification and representative images of Tuj1 positive sensory fibers (green, arrowheads) entering the epidermis per 225 µm epidermal length in thick (C-D) and thin (E-F) skin, DAPI counterstain (blue); scale bar = 25 µm; *p
    Figure Legend Snippet: Loss of Bclw exacerbates paclitaxel-induced neuropathy in vivo . (A) Thermal pain threshold measured as time to lick or withdraw hindpaw on a 50°C hot-plate. (B) Mechanical pain threshold determined from response to von Frey filaments. (C-F) Quantification and representative images of Tuj1 positive sensory fibers (green, arrowheads) entering the epidermis per 225 µm epidermal length in thick (C-D) and thin (E-F) skin, DAPI counterstain (blue); scale bar = 25 µm; *p

    Techniques Used: In Vivo

    Paclitaxel reduces axonal Bclw mRNA and protein levels bclw (A), bcl2 (D) and bclx L (G) mRNA analyzed by qRT-PCR from cell body or axon lysate of compartmented cultures after 24 hours of paclitaxel or vehicle treatment to axons. Data normalized to gapdh ; *p
    Figure Legend Snippet: Paclitaxel reduces axonal Bclw mRNA and protein levels bclw (A), bcl2 (D) and bclx L (G) mRNA analyzed by qRT-PCR from cell body or axon lysate of compartmented cultures after 24 hours of paclitaxel or vehicle treatment to axons. Data normalized to gapdh ; *p

    Techniques Used: Quantitative RT-PCR

    Paclitaxel reduces translation of Bclw via reduction of SFPQ (A) Western blot and (B) quantification of SFPQ protein from cell body or distal axon lysate of compartmented cultures after 24 hours of paclitaxel treatment to axons; data normalized to actin; *p
    Figure Legend Snippet: Paclitaxel reduces translation of Bclw via reduction of SFPQ (A) Western blot and (B) quantification of SFPQ protein from cell body or distal axon lysate of compartmented cultures after 24 hours of paclitaxel treatment to axons; data normalized to actin; *p

    Techniques Used: Western Blot

    Axonal Bclw prevents paclitaxel-induced degeneration (A) Binarized images of Tuj1 immunostaining of axons treated with paclitaxel or vehicle after protein transfection with Bclw, Bcl2, Bclx L . (B) Degeneration index of (A) and untransfected (Untrans) control; *p
    Figure Legend Snippet: Axonal Bclw prevents paclitaxel-induced degeneration (A) Binarized images of Tuj1 immunostaining of axons treated with paclitaxel or vehicle after protein transfection with Bclw, Bcl2, Bclx L . (B) Degeneration index of (A) and untransfected (Untrans) control; *p

    Techniques Used: Immunostaining, Transfection

    Paclitaxel acts locally to induce axon degeneration without cell body apoptosis (A) Tuj1 immunostaining and corresponding binarized images of axons of E15 DRG neurons grown in compartmented cultures treated with 30 nM paclitaxel or DMSO vehicle control for 24 hours to cell body (left) or distal axon (right) compartments; scale bar = 40 µm. Red boxes outline regions shown at higher magnification in the center panels. Features characteristic of degenerating axons are seen: red arrowheads indicate a “beads on a string” appearance and the red lines indicate interruptions in Tuj1 continuity. (B) Quantification of axonal degeneration: ratio of area of fragmented axons to total axon area (degeneration index); *p
    Figure Legend Snippet: Paclitaxel acts locally to induce axon degeneration without cell body apoptosis (A) Tuj1 immunostaining and corresponding binarized images of axons of E15 DRG neurons grown in compartmented cultures treated with 30 nM paclitaxel or DMSO vehicle control for 24 hours to cell body (left) or distal axon (right) compartments; scale bar = 40 µm. Red boxes outline regions shown at higher magnification in the center panels. Features characteristic of degenerating axons are seen: red arrowheads indicate a “beads on a string” appearance and the red lines indicate interruptions in Tuj1 continuity. (B) Quantification of axonal degeneration: ratio of area of fragmented axons to total axon area (degeneration index); *p

    Techniques Used: Immunostaining

    Related Articles

    MTT Assay:

    Article Title: PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of MRP7 (ABCC10) transporter
    Article Snippet: .. Paclitaxel, docetaxel, vinblastine, DMSO, MTT and other chemicals were purchased from Sigma Chemicals (St. Louis, MO, USA). .. The MRP7 cDNA was generously provided by Dr Gary Kruh (University of Illinois, Chicago, IL, USA) and inserted into the pcDNA3.1 expression vector.

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99
    Millipore paclitaxel
    The Bclw BH4 domain is sufficient to prevent <t>paclitaxel-induced</t> axon degeneration (A) Schematic of stabilized alpha-helix of Bcl2 domain (SAHB) peptides modeled after the BH4 domains of Bclw (PDB ID 4CIM, aa 12-31), Bcl2 (PDB ID 2XA0, aa 13-32), and Bclx L (PDB ID 4QVE, aa 6-26). (B) Percent release of ANTS/DPX encapsulated liposomes in the presence of Bax, Bim SAHB A2 , and/or Bclw BH4 SAHB A as indicated; n=3; data represent mean ± SD. (C) Axons from compartmented cultures after protein transfection with FITC-BH4 SAHB peptides of Bclw, Bcl2, or Bclx L showing FITC signal (left) and Tuj1 signal (right); scale bar = 20 µm. (D) Degeneration index of axons treated with paclitaxel or DMSO after protein transfection of FITC-BH4 SAHB-Bclw, Bcl2, or Bclx L into axons; *p
    Paclitaxel, supplied by Millipore, used in various techniques. Bioz Stars score: 99/100, based on 327 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/paclitaxel/product/Millipore
    Average 99 stars, based on 327 article reviews
    Price from $9.99 to $1999.99
    paclitaxel - by Bioz Stars, 2020-09
    99/100 stars
      Buy from Supplier

    89
    Millipore dehydrated ethanol
    The Bclw BH4 domain is sufficient to prevent <t>paclitaxel-induced</t> axon degeneration (A) Schematic of stabilized alpha-helix of Bcl2 domain (SAHB) peptides modeled after the BH4 domains of Bclw (PDB ID 4CIM, aa 12-31), Bcl2 (PDB ID 2XA0, aa 13-32), and Bclx L (PDB ID 4QVE, aa 6-26). (B) Percent release of ANTS/DPX encapsulated liposomes in the presence of Bax, Bim SAHB A2 , and/or Bclw BH4 SAHB A as indicated; n=3; data represent mean ± SD. (C) Axons from compartmented cultures after protein transfection with FITC-BH4 SAHB peptides of Bclw, Bcl2, or Bclx L showing FITC signal (left) and Tuj1 signal (right); scale bar = 20 µm. (D) Degeneration index of axons treated with paclitaxel or DMSO after protein transfection of FITC-BH4 SAHB-Bclw, Bcl2, or Bclx L into axons; *p
    Dehydrated Ethanol, supplied by Millipore, used in various techniques. Bioz Stars score: 89/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dehydrated ethanol/product/Millipore
    Average 89 stars, based on 6 article reviews
    Price from $9.99 to $1999.99
    dehydrated ethanol - by Bioz Stars, 2020-09
    89/100 stars
      Buy from Supplier

    Image Search Results


    The Bclw BH4 domain is sufficient to prevent paclitaxel-induced axon degeneration (A) Schematic of stabilized alpha-helix of Bcl2 domain (SAHB) peptides modeled after the BH4 domains of Bclw (PDB ID 4CIM, aa 12-31), Bcl2 (PDB ID 2XA0, aa 13-32), and Bclx L (PDB ID 4QVE, aa 6-26). (B) Percent release of ANTS/DPX encapsulated liposomes in the presence of Bax, Bim SAHB A2 , and/or Bclw BH4 SAHB A as indicated; n=3; data represent mean ± SD. (C) Axons from compartmented cultures after protein transfection with FITC-BH4 SAHB peptides of Bclw, Bcl2, or Bclx L showing FITC signal (left) and Tuj1 signal (right); scale bar = 20 µm. (D) Degeneration index of axons treated with paclitaxel or DMSO after protein transfection of FITC-BH4 SAHB-Bclw, Bcl2, or Bclx L into axons; *p

    Journal: Neuron

    Article Title: Paclitaxel reduces axonal Bclw to initiate IP3R1-dependent axon degeneration

    doi: 10.1016/j.neuron.2017.09.034

    Figure Lengend Snippet: The Bclw BH4 domain is sufficient to prevent paclitaxel-induced axon degeneration (A) Schematic of stabilized alpha-helix of Bcl2 domain (SAHB) peptides modeled after the BH4 domains of Bclw (PDB ID 4CIM, aa 12-31), Bcl2 (PDB ID 2XA0, aa 13-32), and Bclx L (PDB ID 4QVE, aa 6-26). (B) Percent release of ANTS/DPX encapsulated liposomes in the presence of Bax, Bim SAHB A2 , and/or Bclw BH4 SAHB A as indicated; n=3; data represent mean ± SD. (C) Axons from compartmented cultures after protein transfection with FITC-BH4 SAHB peptides of Bclw, Bcl2, or Bclx L showing FITC signal (left) and Tuj1 signal (right); scale bar = 20 µm. (D) Degeneration index of axons treated with paclitaxel or DMSO after protein transfection of FITC-BH4 SAHB-Bclw, Bcl2, or Bclx L into axons; *p

    Article Snippet: Paclitaxel was prepared as 1 part 6 mg/mL paclitaxel stock solution diluted in vehicle (1:1 v/v Cremophor EL [EMD Millipore] and dehydrated ethanol) and 2 parts sterile saline and injected at 10 µL/g.

    Techniques: Transfection

    Loss of Bclw exacerbates paclitaxel-induced neuropathy in vivo . (A) Thermal pain threshold measured as time to lick or withdraw hindpaw on a 50°C hot-plate. (B) Mechanical pain threshold determined from response to von Frey filaments. (C-F) Quantification and representative images of Tuj1 positive sensory fibers (green, arrowheads) entering the epidermis per 225 µm epidermal length in thick (C-D) and thin (E-F) skin, DAPI counterstain (blue); scale bar = 25 µm; *p

    Journal: Neuron

    Article Title: Paclitaxel reduces axonal Bclw to initiate IP3R1-dependent axon degeneration

    doi: 10.1016/j.neuron.2017.09.034

    Figure Lengend Snippet: Loss of Bclw exacerbates paclitaxel-induced neuropathy in vivo . (A) Thermal pain threshold measured as time to lick or withdraw hindpaw on a 50°C hot-plate. (B) Mechanical pain threshold determined from response to von Frey filaments. (C-F) Quantification and representative images of Tuj1 positive sensory fibers (green, arrowheads) entering the epidermis per 225 µm epidermal length in thick (C-D) and thin (E-F) skin, DAPI counterstain (blue); scale bar = 25 µm; *p

    Article Snippet: Paclitaxel was prepared as 1 part 6 mg/mL paclitaxel stock solution diluted in vehicle (1:1 v/v Cremophor EL [EMD Millipore] and dehydrated ethanol) and 2 parts sterile saline and injected at 10 µL/g.

    Techniques: In Vivo

    Paclitaxel reduces axonal Bclw mRNA and protein levels bclw (A), bcl2 (D) and bclx L (G) mRNA analyzed by qRT-PCR from cell body or axon lysate of compartmented cultures after 24 hours of paclitaxel or vehicle treatment to axons. Data normalized to gapdh ; *p

    Journal: Neuron

    Article Title: Paclitaxel reduces axonal Bclw to initiate IP3R1-dependent axon degeneration

    doi: 10.1016/j.neuron.2017.09.034

    Figure Lengend Snippet: Paclitaxel reduces axonal Bclw mRNA and protein levels bclw (A), bcl2 (D) and bclx L (G) mRNA analyzed by qRT-PCR from cell body or axon lysate of compartmented cultures after 24 hours of paclitaxel or vehicle treatment to axons. Data normalized to gapdh ; *p

    Article Snippet: Paclitaxel was prepared as 1 part 6 mg/mL paclitaxel stock solution diluted in vehicle (1:1 v/v Cremophor EL [EMD Millipore] and dehydrated ethanol) and 2 parts sterile saline and injected at 10 µL/g.

    Techniques: Quantitative RT-PCR

    Paclitaxel reduces translation of Bclw via reduction of SFPQ (A) Western blot and (B) quantification of SFPQ protein from cell body or distal axon lysate of compartmented cultures after 24 hours of paclitaxel treatment to axons; data normalized to actin; *p

    Journal: Neuron

    Article Title: Paclitaxel reduces axonal Bclw to initiate IP3R1-dependent axon degeneration

    doi: 10.1016/j.neuron.2017.09.034

    Figure Lengend Snippet: Paclitaxel reduces translation of Bclw via reduction of SFPQ (A) Western blot and (B) quantification of SFPQ protein from cell body or distal axon lysate of compartmented cultures after 24 hours of paclitaxel treatment to axons; data normalized to actin; *p

    Article Snippet: Paclitaxel was prepared as 1 part 6 mg/mL paclitaxel stock solution diluted in vehicle (1:1 v/v Cremophor EL [EMD Millipore] and dehydrated ethanol) and 2 parts sterile saline and injected at 10 µL/g.

    Techniques: Western Blot

    Axonal Bclw prevents paclitaxel-induced degeneration (A) Binarized images of Tuj1 immunostaining of axons treated with paclitaxel or vehicle after protein transfection with Bclw, Bcl2, Bclx L . (B) Degeneration index of (A) and untransfected (Untrans) control; *p

    Journal: Neuron

    Article Title: Paclitaxel reduces axonal Bclw to initiate IP3R1-dependent axon degeneration

    doi: 10.1016/j.neuron.2017.09.034

    Figure Lengend Snippet: Axonal Bclw prevents paclitaxel-induced degeneration (A) Binarized images of Tuj1 immunostaining of axons treated with paclitaxel or vehicle after protein transfection with Bclw, Bcl2, Bclx L . (B) Degeneration index of (A) and untransfected (Untrans) control; *p

    Article Snippet: Paclitaxel was prepared as 1 part 6 mg/mL paclitaxel stock solution diluted in vehicle (1:1 v/v Cremophor EL [EMD Millipore] and dehydrated ethanol) and 2 parts sterile saline and injected at 10 µL/g.

    Techniques: Immunostaining, Transfection

    Paclitaxel acts locally to induce axon degeneration without cell body apoptosis (A) Tuj1 immunostaining and corresponding binarized images of axons of E15 DRG neurons grown in compartmented cultures treated with 30 nM paclitaxel or DMSO vehicle control for 24 hours to cell body (left) or distal axon (right) compartments; scale bar = 40 µm. Red boxes outline regions shown at higher magnification in the center panels. Features characteristic of degenerating axons are seen: red arrowheads indicate a “beads on a string” appearance and the red lines indicate interruptions in Tuj1 continuity. (B) Quantification of axonal degeneration: ratio of area of fragmented axons to total axon area (degeneration index); *p

    Journal: Neuron

    Article Title: Paclitaxel reduces axonal Bclw to initiate IP3R1-dependent axon degeneration

    doi: 10.1016/j.neuron.2017.09.034

    Figure Lengend Snippet: Paclitaxel acts locally to induce axon degeneration without cell body apoptosis (A) Tuj1 immunostaining and corresponding binarized images of axons of E15 DRG neurons grown in compartmented cultures treated with 30 nM paclitaxel or DMSO vehicle control for 24 hours to cell body (left) or distal axon (right) compartments; scale bar = 40 µm. Red boxes outline regions shown at higher magnification in the center panels. Features characteristic of degenerating axons are seen: red arrowheads indicate a “beads on a string” appearance and the red lines indicate interruptions in Tuj1 continuity. (B) Quantification of axonal degeneration: ratio of area of fragmented axons to total axon area (degeneration index); *p

    Article Snippet: Paclitaxel was prepared as 1 part 6 mg/mL paclitaxel stock solution diluted in vehicle (1:1 v/v Cremophor EL [EMD Millipore] and dehydrated ethanol) and 2 parts sterile saline and injected at 10 µL/g.

    Techniques: Immunostaining